Who are Placebo, Omeprazole or Rabeprazole, Clarithromycin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-omeprazole-or-rabeprazole-clarithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo, Omeprazole or Rabeprazole, Clarithromycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo, Omeprazole or Rabeprazole, Clarithromycin (Placebo, Omeprazole or Rabeprazole, Clarithromycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor, Macrolide antibiotic. Area: Gastrointestinal, Infectious diseases.

phase 3 Proton pump inhibitor, Macrolide antibiotic H+/K+ ATPase, 50S ribosomal subunit Gastrointestinal, Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

Placebo, Omeprazole or Rabeprazole, Clarithromycin (Placebo, Omeprazole or Rabeprazole, Clarithromycin) — National Cancer Center, Korea. Omeprazole and Rabeprazole are proton pump inhibitors that reduce gastric acid secretion, while Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo, Omeprazole or Rabeprazole, Clarithromycin TARGET	Placebo, Omeprazole or Rabeprazole, Clarithromycin	National Cancer Center, Korea	phase 3	Proton pump inhibitor, Macrolide antibiotic	H+/K+ ATPase, 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor, Macrolide antibiotic class)

National Cancer Center, Korea · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo, Omeprazole or Rabeprazole, Clarithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-omeprazole-or-rabeprazole-clarithromycin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab